TScan Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
TScan Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • TScan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$29.9M, a 30% decline year-over-year.
  • TScan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$111M, a 26% decline year-over-year.
  • TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$89.2M, a 34.7% decline from 2022.
  • TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$66.2M, a 36.2% decline from 2021.
  • TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$48.6M, a 86.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$89.2M -$23M -34.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 -$66.2M -$17.6M -36.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 -$48.6M -$22.5M -86.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
2020 -$26.1M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.